Lixte Biotechnology Holdings Inc (XETR:8640) Share Price

Company Profile

Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USA
T: +1 631 830-7092
https://www.lixte.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4

Recommended

Higher sales and a new loan facility increase our conviction.

Shane Ponraj, CFA | 15 January 2026

We’ve raised our fair value estimate of Taiwan Semiconductor stock.

Phelix Lee | 15 January 2026

Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.

Matthew Dolgin, CFA | 15 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,226.70	45.90	0.50%
CAC 40	8,258.94	54.18	-0.65%
DAX 40	25,297.13	55.26	-0.22%
Dow JONES (US)	49,412.39	30.05	-0.06%
FTSE 100	10,235.29	3.65	-0.04%
HKSE	26,844.96	78.66	-0.29%
NASDAQ	23,540.09	10.07	0.04%
Nikkei 225	53,936.17	174.33	-0.32%
NZX 50 Index	13,718.10	58.31	0.43%
S&P 500	6,950.30	5.83	0.08%
S&P/ASX 200	8,903.90	48.10	0.54%
SSE Composite Index	4,101.91	10.69	-0.26%